|
sars-cov-2 |
14 |
|
ace2 |
13 |
|
covid-19 |
13 |
|
rnai |
13 |
|
sace2 |
13 |
|
viral entry |
10 |
|
genome mutation |
9 |
|
human respiratory syncytial virus |
9 |
|
influenza a virus |
9 |
|
lethal mouse model |
9 |
|
lung pathology |
9 |
|
antiviral peptide |
8 |
|
human defensin peptide |
8 |
|
influenza virus |
8 |
|
rhinovirus |
8 |
|
anti-influenza |
7 |
|
avian influenza a/h7n9 virus |
7 |
|
cross-protection |
7 |
|
defective interfering viral genome |
7 |
|
h7n7 virus |
7 |
|
illumina sequencing |
7 |
|
immune response |
7 |
|
immunology |
7 |
|
mutation |
7 |
|
pa protein |
7 |
|
pathogenicity |
7 |
|
polymerase assembly |
7 |
|
single molecule real time sequencing |
7 |
|
viral replication |
7 |
|
virology |
7 |
|
diagnostic assay |
6 |
|
influenza |
6 |
|
next-generation sequencing |
6 |
|
cross protection |
4 |
|
h7n9 |
4 |
|
m2e |
4 |
|
peptide vaccine |
4 |
|
h5n1 |
3 |
|
mammal |
3 |
|
receptor binding |
3 |
|
transmission |
3 |
|
antiviral |
2 |
|
broad-spectrum |
2 |
|
entry inhibitor |
2 |
|
peptides |
2 |
|
respiratory organs - diseases |
2 |
|
respiratory virus |
2 |
|
virus diseases |
2 |
|
fn-lcb1 |
1 |
|
intranasal prophylactic |
1 |
|
viral transmission |
1 |
